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Abstract
The objective was to establish and standardise a broth microdilution susceptibility testing
method for porcineBordetella(B.) bronchiseptica. B. bronchiseptica isolates from different
geographical regions and farms were genotyped bymacrorestriction analysis and subse-
quent pulsed-field gel electrophoresis. One reference and one type strain plus two field iso-
lates of B. bronchisepticawere chosen to analyse growth curves in four different media:
cation-adjusted Mueller-Hinton broth (CAMHB) with and without 2% lysed horse blood, Brain-
Heart-Infusion (BHI), and Caso broth. The growth rate of each test strain in eachmediumwas
determined by culture enumeration and the suitability of CAMHBwas confirmed by compara-
tive statistical analysis. Thereafter, reference and type strain and eight epidemiologically unre-
lated field isolates of B. bronchisepticawere used to test the suitability of a broth microdilution
susceptibility testing method following CLSI-approved performance standards given in docu-
ment VET01-A4. Susceptibility tests, using 20 antimicrobial agents, were performed in five
replicates, and data were collected after 20 and 24 hours incubation and statistically ana-
lysed. Due to the low growth rate of B. bronchiseptica, an incubation time of 24 hours resulted
in significantly more homogeneous minimum inhibitory concentrations after five replications
compared to a 20-hour incubation. An interlaboratory comparison trial including susceptibility
testing of 24 antimicrobial agents revealed a high mean level of reproducibility (97.9%) of the
modified method. Hence, in a harmonization for broth microdilution susceptibility testing ofB.
bronchiseptica, an incubation time of 24 hours in CAMHBmedium with an incubation temper-
ature of 35°C and an inoculum concentration of approximately 5 x 105cfu/ml was proposed.
Introduction
Bordetella bronchiseptica, a strict aerobic, gram-negative coccobacillus belongs to the genus
Bordetella within the alcaligenaceae family [1]. This pathogen is known to cause respiratory
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tract infections in mammals [2]. In infected pigs, the pathogen can lead to symptoms ranging
from mild bronchitis to severe bronchopneumonia. It is also involved in atrophic rhinitis,
associated with toxogenic strains of Pasteurella multocida, which can lead to severe distor-
sion and atrophy of the turbinate bones in the nasal terminus [3–5]. In dogs it causes tra-
cheobronchitis and is one of the main pathogens of kennel cough [6]. Tracheobronchitis,
conjunctivitis, rhinitis and pneumonia occurs in cats [7]. Respiratory tract infections due to
B. bronchiseptica are also known in rabbits and guinea pigs [8].
Although primarily an animal pathogen, B. bronchisepticamay also cause pertussis-like re-
spiratory symptoms in humans and is occasionally isolated from immunosuppressed hosts [9–
11]. The pathogen is closely related to Bordetella pertussis, that causes whooping cough in hu-
mans, even though B. bronchiseptica does not harbor the same virulence factors [12, 13]. For
systematic therapy of both human and animal patients and to reduce the chance of the selec-
tion of resistances against antimicrobial agents, increased knowledge about antimicrobial sus-
ceptibility of veterinary pathogens is required. A standardised method of susceptibility testing
would provide more stable MIC data for treatment recommendations for veterinarians in
the field.
However, currently there is a standardised protocol for non-fastidious, rapidly replicating
bacteria available to perform broth microdilution susceptibility testing. Testing usually follows
the recommendations given in CLSI-document VET01-A4, even though the applicability for B.
bronchiseptica has not been demonstrated [14]. B. bronchiseptica is the least fastidious organ-
ism within the Bordetella genus, but due to its relatively slow growth compared to other rapidly
replicating bacteria, it is necessary to prove if the same testing conditions apply [15]. Therefore,
the aim of this study was to provide a basis for the harmonization of broth microdilution sus-
ceptibility testing for B. bronchiseptica.
Materials and Methods
Bacterial isolates and macrorestriction analysis
For this study, the reference strain DSM 10303 (Leibniz-Institute DSMZ, German Collection
of Microorganism and Cellcultures, Braunschweig, Germany) and the type strain DSM
13414 (DSMZ) of B. bronchiseptica plus 17 porcine field isolates were used. The isolates were
provided from diagnostic laboratories in Germany and originated from different farms and
geographically distinct regions across Germany. They were isolated from both diseased and
healthy swine collected between 2010 and 2012. B. bronchiseptica isolates were grown on Co-
lumbia sheep blood agar (Oxoid, Wesel, Germany) in ambient air at 35°C ± 1.0°C for 24
hours ± 2 hours. Species identification of the isolates was confirmed by a previously pub-
lished B. bronchiseptica specific PCR which targets the flagellin flaA gene by amplification of
a 237 bp fragment [11]. To investigate the clonality of the isolates, macrorestriction analysis
was performed. For this, the XbaI digested fragments of B. bronchiseptica genomic DNA
were separated in a CHEF DR II system (BioRad, Munich, Germany). The pulse time was in-
creased from 7 to 20 s for 14 hours and from 30 to 50 s for 10 hours. The criterion of> 6
bands difference was used to define unrelated isolates, differences in 4–6 bands or 2–3 bands
were defined as possibly related and closely related, respectively [16]. Based on the results of
the macrorestriction analysis, two unrelated isolates (Bb5/12, Bb24/12) and both reference
and type strains of B. bronchiseptica were chosen for the determination of growth curves. Iso-
lates were collected in Germany in 2012 from diseased piglets. These four isolates plus six ad-
ditional field isolates were used for susceptibility testing. The six field isolates were collected
from different geographical regions and different farms in Germany 2010 to 2012 from dis-
eased piglets and fattening pigs.
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Growth curves
Growth curves of the strains DSM 10303, DSM 13414, and field isolates Bb5/12 and Bb24/12
were generated over 48 hours by measuring the optical density OD600 on a UV-visible spectro-
photometer (Varian Cary-100, Mulgrave Victoria, Australia), as well as by culture-based enu-
meration. For all four isolates an overnight culture was carried out in CAMHB (Oxoid, Wesel,
Germany) at 35°C in ambient air. The overnight culture was adjusted to 0.5 McFarland standard
and a 1:100 dilution was carried out in 0.9% saline. From this diluted bacterial suspension 100 μl
was added to 100 ml of each medium to reach a start cfu/mL of approximately 103 cfu/mL.
Isolates were cultured in cation-adjusted Mueller-Hinton broth (CAMHB), CAMHB plus
2% (v/v) lysed horse blood, Brain-Heart-Infusion (BHI) (Becton Dickinson, Heidelberg, Ger-
many) and Caso broth (Sigma-Aldrich, Seelze, Germany), which are frequently used media for
the cultivation of Bordetella spp. [17–19]. Incubation was performed at 35°C in ambient air.
Sampling was performed every two hours during the first 26 hours and, thereafter every six
hours. At each sampling time, starting at hour 0, a 10-fold serial dilution in 0.9% saline was
done for every isolate, and four different dilutions were plated in duplicate on Columbia sheep
blood agar. Enumeration plates were incubated at 35°C in ambient air. To calculate the average
of colony forming units, two dilutions between 5 and approximately 200 cfu/mL were counted
from the plated dilutions and the mean value of the two dilutions was determined. All experi-
ments were performed three times independently.
Susceptibility testing
The B. bronchiseptica reference and type strains (DSM 10303, DSM 13414) plus eight epidemio-
logically unrelated isolates or isolates differing in at least 3–6 bands were used to evaluate the
suitability of broth microdilution susceptibility test conditions for B. bronchiseptica. Inoculum
density (approximately 5 x 105 cfu/mL), growth medium (CAMHB) and incubation conditions
(35°C in ambient air) followed Clinical and Laboratory Standards Institute (CLSI, Wayne, PA,
USA) guidelines for rapidly growing aerobic bacteria isolated from animals [14]. Isolates were in-
vestigated against a panel of 20 antibiotics/antibiotic combinations using a customised 50 μl/well
volume microtiter plate (Sensititre, Trek Diagnostic Systems, East Grinstead, UK) layout. A
broad range of antimicrobial agents (Table 1) was tested to prove the stability of the measured
values across a broader spectrum, including several antimicrobial agents that are not currently li-
censed for food animals. In addition, some antimicrobial agents, for which a low susceptibility
has been previously reported, e.g. cephalosporins, were included enabling assessment of homoge-
neity of MIC values in five replicates [1, 20]. MICs were determined visually for each isolate by
the same person after 20 and 24 hours. Final inoculum concentration was verified by diluting the
inoculum in a 10-fold serial dilution in 0.9% saline, plating the bacterial suspension on Columbia
sheep blood agar and determining cfu on agar plates after incubation. An inoculum density of
approximately 5 x 105 cfu was targeted. For quality control purposes, the Escherichia coli strain
ATCC 25922 was used, for which acceptable quality control ranges of MIC values for broth
microdilution are available [14]. Tests were repeated independently five times.
Statistical analyses
The primary aim of this study was to compare the stability of MIC after 20 or 24 hours incuba-
tion time. Of secondary interest were the exploration of growth curves and the investigation of
differences in MIC values depending on the incubation time.
To investigate whether the stability of the MIC values differed between the two incubation
times, for each combination of isolate, antibiotic agent, and incubation time, MIC data consist-
ing of five measurements was summarized to a dichotomous outcome. The outcome was set to
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1 if all five measurements were equal and 0 otherwise. Stability of measurements was analyzed
with a multi-factorial logistic regression model for mixed effects with dichotomous stability de-
pending on incubation time, antibiotic agent and isolate (fixed effects) and identification of the
stability measurement (random effect) [21]. Global p-values for all three factors were comput-
ed, and for the incubation time, the odds ratio with the corresponding two-sided 95%-confi-
dence interval was estimated.
The growth of B. bronchiseptica isolates depending on the four media at a specific time
point was computed with marginal confidence intervals based on an analysis of covariance
(ANCOVA) for repeated measurements. For each individual strain, a model was computed
consisting of the culture enumeration log-transformed to base 10 depending on time of mea-
surement, medium, the interaction of time and medium, and the covariate baseline measure-
ment. Furthermore, covariance among the time points was modelled with a first-order
autoregressive structure [21]. Resulting confidence intervals of the interaction time by medium
were examined for all medium-isolate combinations in three independent experiments.
Differences in MIC values depending on incubation time were investigated with an
ANOVA with mixed effects modeling the log-transformed MIC values depending on the fixed
factors of incubation time, antibiotic agent, and isolate, and sample identification as the ran-
dom effect. Because the distribution of MIC values was skewed to the right and a two-fold dilu-
tion series was used, data was log-transformed to base 2. In addition to the global p-values for
each factor, difference in incubation time means and the corresponding confidence interval on
Table 1. Tested antimicrobial agents and their ranges.
Antimicrobial agent Ranges (μg/ml)
ampicillin 0.03–64
amoxicillin/clavulanic acid 2:1 ratio 0.03/0.015–64/32
ceftiofur 0.03–64
cefquinome 0.015–32
cefoperazone 0.06–32
cefotaxime 0.015–32
chloramphenicol 0.5–64
ciproﬂoxacin1 0.008–16
colistin 0.03–16
doxycycline 0.06–128
enroﬂoxacin 0.008–16
ﬂorfenicol 0.12–256
gentamicin 0.12–256
imipenem 0.015–32
marboﬂoxacin1 0.008–16
nalidixic acid 0.06–128
neomycin1 0.03–128
penicillin 0.015–32
spiramycin 0.06–128
streptomycin1 0.25–256
tiamulin 0.03–64
tetracycline 0.12–128
tilmicosin 0.06–64
trimethoprim/sulfamethoxazole (1:19 ratio) 0.015/0.3–32/608
1 these antimicrobial agents were included only in the interlaboratory comparison.
doi:10.1371/journal.pone.0123883.t001
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the logarithmic scale was estimated. After back-transformation, this estimate and the confi-
dence interval corresponded to the ratio of geometric means of incubation times.
Except for the analysis of growth curves, interactions (e.g. odds ratios for incubation time
dependent on antibiotic agent) were omitted in order to generalize usability. The type I
error was set at 5% (two-sided). SAS System (Cary, NC, USA), Version 9.3., was used for all
analyses [22].
Interlaboratory comparison
An interlaboratory comparison, organized by the Federal Office of Consumer Protection
and Food Safety (BVL, Berlin, Germany), was performed by a total of ten laboratories to de-
termine the reproducibility of the method. All laboratories are experienced in conducting
susceptibility testing of bacterial pathogens and they perform MICs routinely. B. bronchi-
septica reference strain DSM10303, field isolate Bb5/12 and quality control strain E. coli
ATCC25922 were sent to all participating laboratories together with microtiter plates (Sen-
sititre, Trek Diagnostic Systems, East Grinstead, UK). For each replication, three microtiter
plates with a total of 24 antimicrobial agents (Table 1) were used to obtain MIC data of
broth microdilution susceptibility testing in CAMHB. An incubation temperature of 35°C
and incubation time of 24 hours were chosen for the interlaboratory comparison. Cell den-
sities and purity control were determined by colony count check immediately after inocula-
tion and sub-culturing of strains, respectively, by each laboratory in each experimental
replication. Testing in each laboratory took place within four weeks and was repeated inde-
pendently three times. Analysis of MIC data was performed by determining the deviation
of the modal value from MIC in log2-steps for each laboratory, bacterial strain and antimi-
crobial agent by the BVL, Berlin. Modal value plus minus one dilution step were chosen as
a respectable determination.
Results
Clonality of B. bronchiseptica isolates and growth behavior
Although originating from different geographical regions in Germany, 11 of the 17 initially
tested B. bronchiseptica isolates showed similar fragment patterns during macrorestriction
analysis (Fig A in S1 File). Therefore, the two reference strains and eight field isolates (Bb24/
12, Bb77/10, Bb5/12, Bb101/12, Bb41/12, Bb174/11, Bb164/11, Bb159/11) differing in at least 3
to>6 fragments were chosen for further comparison tests.
Growth curves of four isolates cultured in different media showed a difference in the results
between optical density (OD600) and culture enumeration (cfu/mL). While the mean value
of three replications of optical density measurement showed a beneficial growth in CAMHB +
2% lysed horse blood, the mean value of three replications of cfu/mL revealed an almost con-
sistent growth in the four different media (Fig B–I in S1 File). However, results from culture-
based enumeration demonstrated a slow but sufficient growth of B. bronchiseptica in CAMHB
in comparison to other rapid replicating bacteria like E. coli or Salmonella Enteritidis [15, 23].
When considering single measuring points, statistical analysis revealed significant differences
in growth for some isolate-media combinations, although all differences were less than one
log step (Fig F–I in S1 File). The greatest difference was found for the DSM 10303 strain,
where the difference CAMHB—CAMHB+HB after 14 hours incubation was -0.925 cfu/mL
log10 (95%-confidence interval: -1.255; -0.595). However, after 22 to 24 hours, the growth of
B. bronchiseptica reached the beginning of the stationary phase at approximately 109 cfu/mL
in all four media tested.
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Susceptibility testing
Overall, MIC values of the combination of ten isolates, twenty antimicrobial agents, two incu-
bation times and five replicates resulting in 2,000 measurements were investigated (Table A
in S2 File).
For statistical evaluation, each combination of five replicates was summarised to 0 (varying
measurements) or 1 (stable results). The proportion of stable MIC values in the entire sample
was 160/400 = 40%. After 24 hours of incubation, in 97 of 200 combinations (48.5%) of isolate
and antibiotic agent the five MIC replicates were equal compared to 63 out of 200 (31.5%) after
20 hours of incubation. Detailed results of the relative frequencies of the MIC mode for each
combination of antimicrobial agent and bacterial strain are shown in Figs 1 and 2 for 20 and 24
hours incubation time. In multi-factorial logistic regression analysis, the odds ratio for incuba-
tion time was 2.535 (95%-CI = [1.578; 4.071], p = 0.0001) stressing the higher stability of longer
incubation. Differences in stability were also found among antibiotic agents (p0.0001) and
isolates (p = 0.0293).
Overall, increase in incubation time to 24 hours increased the geometric mean MIC value
to 5.333 (9.351) compared to 4.305 (9.452) after 20 hours of incubation. In multi-factorial
ANOVA, the ratio of geometric means was 1.239 (95%-CI = 1.181; 1.299, p0.0001) indicat-
ing an increase in MIC values with longer incubation (Fig 3). MIC values differed among the
antibiotic agents (p0.0001) and isolates (p0.0001). Eight of 10 isolates showed more ho-
mogenous MICs after 24 hours than after the 20-hour incubation time recommended for rap-
idly growing bacteria. Only reference strain DSM 10303 and field isolate Bb5/12 showed more
homogenous MICs after 20 hours incubation time. Ampicillin, amoxicillin/clavulanic acid,
cefquinome, chloramphenicol, enrofloxacin, florfenicol, spiramycin tiamulin, tilmicosin and
Fig 1. Heat map of the relative frequency [%] of MICmode for each combination of antibiotic agent and bacterial strain (20 hours incubation time)
demonstrated as heat map. A relative frequency of 100% demonstrates five equal measurements.
doi:10.1371/journal.pone.0123883.g001
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Fig 2. Heat map of the relative frequency [%] of MICmode for each combination of antibiotic agent and bacterial strain (24 hours incubation time)
demonstrated as heat map. A relative frequency of 100% demonstrates five equal measurements.
doi:10.1371/journal.pone.0123883.g002
Fig 3. In the left graphic odds and the corresponding 95%-confidence intervals for stable MIC values split by incubation time are shown.Geometric
means and corresponding 95%-confidence intervals for MIC values depending on incubation time are presented in the right graphic. Odds and geometric
means are adjusted for bacteria strain and antibiotic agent.
doi:10.1371/journal.pone.0123883.g003
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trimethoprim/sulfamethoxazole gave the most homogenous MIC values after 24 hours. In
contrast, MICs for doxycycline and colistin were more homogenous after 20 hours. Three an-
timicrobial agents (nalidixic acid, gentamicin and cefotaxime) showed an equal distribution
between 20 and 24 hours. Identical MIC values or more homogenous MICs after 24 hours
were found in imipenem, tetracyclin, penicillin, ceftiofur and cefoperazone. All MIC values
for the quality control strain E. coli ATCC25922 were within the acceptable ranges after 20
and 24 hours of incubation.
Possible violations of the ANOVA assumptions where investigated with a Q-Q-plot and a
histogram of residuals. No considerable violations could be detected.
Interlaboratory comparison
Reliable MIC data were collected by all laboratories participating in the interlaboratory com-
parison trial, whereby the data could be evaluated if the following criteria were met: 1. modus
(entire number of most frequent determined MICs) and value of participant was equal or dif-
fered by plus minus one dilution step for the combination of bacterial strain and antimicrobial
agent; 2. MIC values of reference strain were in context with reference range for each antimi-
crobial agent; 3. positive growth control in both wells of microtiterplates; 4. no contamination
was verified in bacterial inoculum and 5. inoculum density exhibited a CFU/mL between 3
x105 and 5 x 105 cfu.
A conformance of 96.7% was accomplished for the field isolate Bb5/12, 98.1% for the type
strain DSM 10303 and 98.9% for E. coli ATCC25922 by all laboratories with a mean of 97.9%.
One laboratory showed a mode of conformance of 94%, two laboratories reached 100% and
three greater than 99%. Four laboratories ranged between 95.8% and 96.9% for all bacterial
species. MICs of each antimicrobial agent ranged between 94.7% and 98.8% conformance,
MICs of colistin (90%) and ceftiofur (91.1%) reached a relatively lower conformity whereas
ampicillin, cefoperazone, cefotaxime, ciprofloxacin, enrofloxacin, gentamicin, imipeneme, na-
lidixic acid and tilmicosin attained 100% conformity. The mean value of the interlaboratory
reproducibility for all antimicrobial agents was 97.9%.
Discussion
Within the genus Bordetella, the species B. bronchiseptica is less fastidious than the human bac-
terial pathogen B. pertussis [15]. Nevertheless, it is important to examine if testing conditions
given in CLSI-document VET01-A4 for rapidly growing bacteria isolated from animals apply
to porcine B. bronchiseptica. For this, growth curves were performed at 35°C in four different
media, which are frequently used for a cultivation of Bordetella spp. Surprisingly, results of
growth curves from optical density readings and culture enumeration differed with OD600
measurements falsely hinting at beneficial growth of B. bronchiseptica in CAMHB + 2% lysed
horse blood. These results pointed out that OD measurement is not adequate for growth deter-
minations of B. bronchiseptica for use with blood-containing media. The tendency of blood to
darken upon exposure to incubation temperatures may be a reason for this observation. Differ-
ences in growth parameters derived from OD readings and colony counts have been reported
previously (e.g. for Listeria monocytogenes) and should be considered when analysing bacterial
growth based on OD data [24, 25].
As culture enumeration detected an almost consistent growth in all media, CAMHB was
chosen for susceptibility testing. CAMHB is a suitable medium for this purpose and is recom-
mended in the CLSI-guidelines for non-fastidious organisms because of its fairly good batch-
to-batch reproducibility for broth dilution susceptibility testing and a low amount of inhibitors
for testing trimethoprim, sulphonamides or tetracyclins [14].
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Nevertheless, the lower growth rate of B. bronchiseptica compared to other rapidly replicat-
ing bacteria indicated that the incubation time should be increased. This was underlined by sta-
tistical analysis of repeated susceptibility testings of 10 B. bronchiseptica isolates, showing a
comparative advantage of 24 hours incubation over 20 hours incubation. For these testings, as
many unrelated B. bronchiseptica as possible were chosen, even though results from macrores-
tiction analysis strongly suggested a clonal relationship between some of the isolates, as previ-
ously reported for B. bronchiseptica isolates from Germany or Korea [8, 26]. It cannot be
excluded that an incubation time longer than 24 hours would lead to more stable results; how-
ever, when considering that the beginning of the stationary phase of growth curves was reached
after 24 hours, extension of the incubation time would be more in line with the testing of rapid-
ly growing bacteria like Salmonella and E. coli. For an incubation time longer than 24 hours,
stability of the antimicrobial agents should be verified by using QC-strains with their estab-
lished MICs and, furthermore, this may be inappropriate for routine diagnostic applications.
Interlaboratory comparisons of the method described here delivered reliable results for
broth microdilution susceptibility testing of B. bronchiseptica in CAMHB with 24 hours incu-
bation time and showed a high level of reproducibility. Only minor variances were seen be-
tween the different laboratories. This outcome was in accordance to the statistical analysis of
the stability of MIC values between 20 and 24 hours incubation time, which showed more ho-
mogenous results after 24 hours incubation time. That a 24 hour incubation time is compara-
tively advantageous for more homogenous MICs is in accordance with recommendations for
fastidious or special problem veterinary pathogens, such as Campylobacter spp. orHistophilus
somni, for which modified incubation times are required [14].
However, the increase in incubation time to 24 hours may lead to minor differences in iso-
late classification according to the veterinary porcine respiratory tract specific B. bronchiseptica
breakpoints. Veterinary specific B. bronchiseptica breakpoints are only available for ampicillin,
florfenicol and tulathromycin (not tested) [14]. These breakpoints were created by using the al-
ready existing method of the CLSI guidelines in document VET01-A4 for rapidly replicating
pathogens of bacteria isolated from animals. Increasing the incubation time to 24 hours would
not lead to a different classification of all 10 porcine B. bronchiseptica isolates for ampicillin.
For florfenicol, there would be no change from susceptible or intermediate to resistant in all 10
porcine isolates. However, a change from susceptible to intermediate is possible for six of the
10 porcine isolates. Whether changing the incubation time to 24 hours would lead to changes
in MIC50 and MIC90 values for antimicrobials without established breakpoints remains to be
elucidated and should be investigated by testing a larger number of B. bronchiseptica isolates.
Even though only one isolate from a dog (type strain DSM 13414) was tested, the growth curves
of the type strain DSM 13414 showed the same low growth rate and reached the stationary phase
after 24 hours. However, to confirm the suitability of the method for isolates from companion ani-
mals, further studies are needed for the testing of isolates from other animal origins than swine.
Conclusion
CAMHB is a suitable medium to use for broth microdilution susceptibility testing of porcine B.
bronchiseptica while still using the recommended inoculum density of approximately 5 x 105
cfu/mL and the incubation temperature of 35°C. An incubation time of 24 hours of the microti-
ter plates could be useful to produce the most reliable and consistent results.
Supporting Information
S1 File. Fig. A. Results of macrorestriction analysis from 17 B. bronchiseptica isolates using Sal-
monella Typhimurium LT2 marker and restriction-endonuclease XbaI. Fig. B. Optical density
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(OD) measurement of B. bronchiseptica reference strain DSM 10303 in four media; mean of
three independent experiments. Fig. C. Optical density (OD) of B. bronchiseptica type strain
DSM 13414 in four media, mean of three independent experiments. Fig. D. Optical density
(OD) of B. bronchiseptica field isolate Bb5/12 in four media, mean of three independent experi-
ments. Fig. E. Optical density (OD) of B. bronchiseptica field isolate Bb24/12 in four media,
mean of three independent experiments. Fig. F. Number (Log cfu/ml) of bacteria (B. bronchi-
septica reference strain DSM 10303) in four media; mean of three independent experiments.
Fig. G. Number (Log cfu/ml) of bacteria (B. bronchiseptica type strain DSM 13414) in four
media; mean of three independent experiments. Fig. H. Number (Log cfu/ml) of bacteria (B.
bronchiseptica field isolate Bb5/12) in four media; mean of three independent experiments.
Fig. I. Number (Log cfu/ml) of bacteria (B. bronchiseptica field isolate Bb24/12) in four media;
mean of three independent experiments.
(DOCX)
S2 File. Table A. MIC values of 10 B. bronchiseptica isolates, 20 antimicrobial agents and two
incubations times in five replicates.
(XLSX)
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